In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine

EL Maynard¹, D Scott³, O Borisov¹, G Smith¹, JE Curtis², A Grishaev², S Krueger²
¹Novavax, Inc., Gaithersburg, MD ²National Institute of Standards and Technology, Gaithersburg, MD

BACKGROUND

ResVax (Pre-fusogenic RSV F nanoparticle vaccine) is currently being assessed in the Prepare™ (Phase 3) trial for the protection of infants via maternal immunization in healthy third trimester pregnant women. The vaccine is based on recombinant near full-length RSV F protein, produced using a baculovirus/Sf9 cell culture platform. RSV F drug substance (DS) contains highly-purified F protein trimers that are formulated with polysorbate 80 (PS80) and assemble into nanoparticles. Structurally, RSV F DS has been characterized by a plethora of biophysical particle characterization methods, including dynamic light scattering (DLS), Analytical Ultracentrifugation (AUC), and Small Angle Scattering (SANS and SAXS) methods, to further our understanding of the nanoparticle assembly of the RSV F-PS80 complex.

OBJECTIVES

To utilize biophysical methods to characterize RSV F nanoparticle in order to understand how RSV F trimers and PS80 interact and influence nanoparticle structure.

METHODS

- Dynamic light scattering (DLS) was used to investigate the relationship between PS80 to RSV F protein ratio and hydrodynamic diameter of the nanoparticle. RSV F was formulated with varying amounts of PS80 in the Drug Substance (DS) formulation buffer. DLS measurements were performed in a multi-well plate format using a Wyatt DynaPro PlateReader II DLS instrument. (Fig. 1)
- Analytical ultracentrifugation (AUC) is orthogonal to DLS and was used to gain further insight into the RSV F-PS80 nanoparticle. Sedimentation of RSV F at varying PS80 concentrations and in the DS formulation buffer was studied using absorbance and interference detection with a Beckman XL-I instrument. (Fig. 2)
- Small angle neutron scattering (SANS) with contrast variation and small angle X-ray scattering (SAXS) were used to understand the spatial relationship between RSV F protein trimers and PS80 in the nanoparticle. SANS/SAXS was performed as a collaboration with National Institute of Standards and Technology (NIST). RSV F sample was buffer exchanged to different target D2O concentrations to achieve contrast matching conditions for protein and detergent. (Fig. 3 and Table 1)

RESULTS

- Fig. 1. Contour plot of DLS data (Dh) as a function of PS80 and RSV F concentration highlights dynamic vaccine nanoparticle. (A) Increasing PS80 concentration highlights dynamic vaccine nanoparticle. (B) Changing the molar ratio of PS80 to RSV F protein modulates hydrodynamic diameter (Dh) of the vaccine nanoparticle. PS80 competes with RSV F trimer-trimer interactions and reduces nanoparticle size. Nanoparticle size in the Drug Substance is controlled by the RSV F manufacturing process.

  - Fig. 2. AUC analysis of RSV F. (A) Sedimentation velocity AUC data of the RSV F nanoparticle vaccine at increasing concentrations of PS80. (B) AUC is a native separation technique that is based on first principles of sedimentation and diffusion. RSV F in DS exists as a discrete population of sedimenting species. Increasing PS80 concentration shifts the nanoparticle population to smaller size, consistent with DLS.

  - Fig. 3. SANS and SAXS data for RSV F DS in formulation buffer containing different concentrations of D2O. (A) 0%, 12%, 99% D2O. (B) 41% D2O (fit to an ellipsoid model). SANS and SAXS data for RSV F DS in formulation buffer containing different concentrations of D2O. (A) 0%, 12%, 99% D2O. (B) 41% D2O (fit to an ellipsoid model).

CONCLUSIONS

- DLS, AUC, and SANS/SAXS data indicate that the RSV F nanoparticle vaccine is a stable colloidal system consisting of highly-purified RSV F protein trimers in complex with PS80 detergent.
- Hydrodynamic size of the RSV F nanoparticle, measured by DLS, was shown to be dependent on the molar ratio of PS80 to RSV F and is controlled through the vaccine manufacturing process.
- AUC and SAXS/SANS measurements of the RSV F nanoparticle mass produced similar results in the range of 1.2 – 1.5 MDa. This mass corresponds to an average of 5 RSV F trimers and 300 PS80 molecules per nanoparticle.
- Modeling of the SANS data indicates PS80 is organized in an ellipsoidal shape at the core of the RSV F nanoparticle. Detailed modeling of the arrangement of RSV F trimers in the nanoparticle is in progress.

REFERENCES